Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment

NeuroImage

Volumn 59, Issue 1, 2012, Pages 212-217

  Thambisetty, Madhav ^a   An, Yang ^a   Kinsey, Anna ^b   Koka, Deepthi ^c   Saleem, Muzamil ^b   Guntert, Andreas ^b   Kraut, Michael ^d   Ferrucci, Luigi ^a   Davatzikos, Christos ^c   Lovestone, Simon ^b   Resnick, Susan M ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Alzheimer's disease (26); Atrophy; Biomarker; Clusterin; Mild cognitive impairment (MCI); Plasma

Indexed keywords

CLUSTERIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN ATROPHY; BRAIN LEVEL; BRAIN REGION; BRAIN SIZE; BRAIN VENTRICLE; CEREBELLUM; CEREBROSPINAL FLUID; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAHIPPOCAMPAL GYRUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUPERIOR TEMPORAL GYRUS; TEMPORAL GYRUS;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; ATROPHY; BRAIN; CLUSTERIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT;

EID: 80054107095     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.07.056     Document Type: Article

References (32)

1. Braak H., Braak E., Bohl J., Bratzke H. Evolution of Alzheimer's disease related cortical lesions. J. Neural Transm. Suppl. 1998, 54:97-106.
2. Braskie M.N., Jahanshad N., Stein J.L., Barysheva M., McMahon K.L., de Zubicaray G.I., Martin N.G., Wright M.J., Ringman J.M., Toga A.W., Thompson P.M. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. J. Neurosci. 2011, 31:6764-6770.
3. Calero M., Rostagno A., Matsubara E., Zlokovic B., Frangione B., Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc. Res. Tech. 2000, 50:305-315.
4. Cummings J.L., Doody R., Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007, 69:1622-1634.
5. DeMattos R.B., O'Dell M.A., Parsadanian M., Taylor J.W., Harmony J.A., Bales K.R., Paul S.M., Aronow B.J., Holtzman D.M. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10843-10848.
6. DeMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O'Dell M.A., Taylor J.W., Harmony J.A., Aronow B.J., Bales K.R., Paul S.M., Holtzman D.M. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 2004, 41:193-202.
7. Driscoll I., Davatzikos C., An Y., Wu X., Shen D., Kraut M., Resnick S.M. Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology 2009, 72:1906-1913.
8. Folstein M.F., Robins L.N., Helzer J.E. The mini-mental state examination. Arch. Gen. Psychiatry 1983, 40:812.
9. French L.E., Wohlwend A., Sappino A.P., Tschopp J., Schifferli J.A. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J. Clin. Invest. 1994, 93:877-884.
10. Giannakopoulos P., Kovari E., French L.E., Viard I., Hof P.R., Bouras C. Possible neuroprotective role of clusterin in Alzheimer's disease: a quantitative immunocytochemical study. Acta Neuropathol. 1998, 95:387-394.
11. Goldszal A.F., Davatzikos C., Pham D.L., Yan M.X., Bryan R.N., Resnick S.M. An image-processing system for qualitative and quantitative volumetric analysis of brain images. J. Comput. Assist. Tomogr. 1998, 22:827-837.
12. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
13. Hartley H.O., Rao J.N. Maximum-likelihood estimation for the mixed analysis of variance model. Biometrika 1967, 54:93-108.
14. Kraemer H.C., Tinklenberg J., Yesavage J.A. 'How far' vs.'how fast' in Alzheimer's disease. The question revisited. Arch. Neurol. 1994, 51:275-279.
15. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fievet N., Barberger-Gateau P., Engelborghs S., De Deyn P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanche H., Dartigues J.F., Tzourio C., Gut I., Van Broeckhoven C., Alperovitch A., Lathrop M., Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099.
16. Lidstrom A.M., Hesse C., Rosengren L., Fredman P., Davidsson P., Blennow K. Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke. J. Alzheimers Dis. 2001, 3:435-442.
17. Lyketsos C.G., Szekely C.A., Mielke M.M., Rosenberg P.B., Zandi P.P. Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. Int. Psychogeriatr. 2008, 20:871-889.
18. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease:report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
19. Naiki H., Nagai Y. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins. J. Biochem. 2009, 146:751-756.
20. Nuutinen T., Suuronen T., Kauppinen A., Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res. Rev. 2009, 61:89-104.
21. Pengas G., Pereira J.M., Williams G.B., Nestor P.J. Comparative reliability of total intracranial volume estimation methods and the influence of atrophy in a longitudinal semantic dementia cohort. J. Neuroimaging 2009, 19:37-46.
22. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004, 256:183-194.
23. Savva G.M., Wharton S.B., Ince P.G., Forster G., Matthews F.E., Brayne C. Age, neuropathology, and dementia. N. Engl. J. Med. 2009, 360:2302-2309.
24. Schrijvers E.M., Koudstaal P.J., Hofman A., Breteler M.M. Plasma clusterin and the risk of Alzheimer disease. JAMA 2011, 305:1322-1326.
25. Seshadri S., Fitzpatrick A.L., Ikram M.A., DeStefano A.L., Gudnason V., Boada M., Bis J.C., Smith A.V., Carassquillo M.M., Lambert J.C., Harold D., Schrijvers E.M., Ramirez-Lorca R., Debette S., Longstreth W.T., Janssens A.C., Pankratz V.S., Dartigues J.F., Hollingworth P., Aspelund T., Hernandez I., Beiser A., Kuller L.H., Koudstaal P.J., Dickson D.W., Tzourio C., Abraham R., Antunez C., Du Y., Rotter J.I., Aulchenko Y.S., Harris T.B., Petersen R.C., Berr C., Owen M.J., Lopez-Arrieta J., Varadarajan B.N., Becker J.T., Rivadeneira F., Nalls M.A., Graff-Radford N.R., Campion D., Auerbach S., Rice K., Hofman A., Jonsson P.V., Schmidt H., Lathrop M., Mosley T.H., Au R., Psaty B.M., Uitterlinden A.G., Farrer L.A., Lumley T., Ruiz A., Williams J., Amouyel P., Younkin S.G., Wolf P.A., Launer L.J., Lopez O.L., van Duijn C.M., Breteler M.M., CHARGE Consortium, GERAD1 Consortium, EADI1 Consortium Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010, 303(18):1832-1840.
26. Shen D., Davatzikos C. HAMMER: hierarchical attribute matching mechanism for elastic registration. IEEE Trans. Med. Imaging 2002, 21:1421-1439.
27. Sihlbom C., Davidsson P., Sjogren M., Wahlund L.O., Nilsson C.L. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochem. Res. 2008, 33:1332-1340.
28. Song F., Poljak A., Smythe G.A., Sachdev P. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res. Rev. 2009, 61:69-80.
29. Thambisetty M., Simmons A., Velayudhan L., Hye A., Campbell J., Zhang Y., Wahlund L.O., Westman E., Kinsey A., Guntert A., Proitsi P., Powell J., Causevic M., Killick R., Lunnon K., Lynham S., Broadstock M., Choudhry F., Howlett D.R., Williams R.J., Sharp S.I., Mitchelmore C., Tunnard C., Leung R., Foy C., O'Brien D., Breen G., Furney S.J., Ward M., Kloszewska I., Mecocci P., Soininen H., Tsolaki M., Vellas B., Hodges A., Murphy D.G.M., Parkins S., Richardson J.C., Resnick S.M., Ferrucci L., Wong D.F., Zhou Y., Muehlboeck S., Evans A., Francis P.T., Spenger C., Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry 2010, 67:739-748.
30. Tschopp J., French L.E. Clusterin: modulation of complement function. Clin. Exp. Immunol. 1994, 97(Suppl. 2):11-14.
31. Whitwell J.L., Jack C.R., Przybelski S.A., Parisi J.E., Senjem M.L., Boeve B.F., Knopman D.S., Petersen R.C., Dickson D.W., Josephs K.A. Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis. Neurobiol. Aging 2011, 32(9):1531-1541.
32. Wyatt A.R., Yerbury J.J., Berghofer P., Greguric I., Katsifis A., Dobson C.M., Wilson M.R. Clusterin facilitates in vivo clearance of extracellular misfolded proteins. Cell. Mol. Life Sci. 2011, [Epub ahead of print].